Related Experiment Video
Updated: Mar 26, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell
Hicham Bouhlal1,2, Hakim Ouled-Haddou1, Véronique Debuysscher1
1Centre Universitaire de Recherche en Santé CURS, CAP-Santé (FED 4231), Université de Picardie Jules Verne, CHU Sud, Amiens, France.
Abstract:
Polo-like kinase PLK1 is a cell cycle protein that plays multiple roles in promoting cell cycle progression. Among the many roles, the most prominent role of PLK1 is to regulate the mitotic spindle formation checkpoint at the M-phase. Recently we reported the expression of SLAMF3 in Hepatocytes and show that it is down regulated in tumor cells of hepatocellular carcinoma (HCC). We also show that the forced high expression level of SLAMF3 in HCC cells controls proliferation by inhibiting the MAPK ERK/JNK and the mTOR pathways. In the present study, we provide evidence that the inhibitory effect of SLAMF3 on HCC proliferation occurs through Retinoblastoma (RB) factor and PLK1-dependent pathway. In addition to the inhibition of MAPK ERK/JNK and the mTOR pathways, expression of SLAMF3 in HCC retains RB factor in its hypophosphorylated active form, which in turn inactivates E2F transcription factor, thereby repressing the expression and activation of PLK1. A clear inverse correlation was also observed between SLAMF3 and PLK expression in patients with HCC. In conclusion, the results presented here suggest that the tumor suppressor potential of SLAMF3 occurs through activation of RB that represses PLK1. We propose that the induction of a high expression level of SLAMF3 in cancerous cells could control cellular mitosis and block tumor progression.
Insights
SLAMF3 suppresses hepatocellular carcinoma (HCC) by maintaining Retinoblastoma (RB) protein activity. This inactivates E2F, repressing Polo-like kinase 1 (PLK1) and inhibiting cancer cell proliferation.
Area of Science:
- Oncology
- Cell Biology
- Molecular Biology
Background:
- Polo-like kinase 1 (PLK1) is crucial for cell cycle progression, particularly M-phase regulation.
- SLAMF3 is downregulated in hepatocellular carcinoma (HCC) and its overexpression inhibits HCC proliferation via MAPK and mTOR pathways.
Purpose of the Study:
- To investigate the mechanism by which SLAMF3 inhibits HCC proliferation.
- To elucidate the role of Retinoblastoma (RB) factor and PLK1 in SLAMF3-mediated tumor suppression.
Main Methods:
- Analysis of SLAMF3 expression in HCC cells and patient tumors.
- Assessment of RB factor phosphorylation status and E2F transcription factor activity.
- Evaluation of PLK1 expression and its correlation with SLAMF3 levels.
Main Results:
- SLAMF3 expression retains RB factor in its hypophosphorylated, active form in HCC cells.
- Active RB inactivates E2F transcription factor, leading to repressed PLK1 expression and activation.
- A significant inverse correlation exists between SLAMF3 and PLK1 expression in HCC patients.
Conclusions:
- SLAMF3 exerts tumor suppressor effects in HCC by activating RB, which subsequently represses PLK1.
- Upregulating SLAMF3 in cancer cells may offer a therapeutic strategy to control mitosis and halt tumor progression.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
Negative Regulator Molecules
The JAK-STAT Signaling Pathway
The Intrinsic Apoptotic Pathway

